The stock looks cheap, but appearances can be deceiving.

Clinical-stage biotechnology firm Recursion announced the release of an open-source biological dataset, RxRx1, which the company has been building for more than five years. The dataset is composed of ...

On sci-fi TV shows like Star Trek, when a doctor needs to cure a disease, they often ask the computer to simulate complex visualizations or go through databases for potential cures. In real life, ...

CEO Chris Gibson highlighted the company's strategic focus on the Recursion Operating System 2.0, emphasizing its capability to improve efficiency in drug discovery and development. Management ...

Recursion stands out as a pure play in AI-powered biotech, using machine learning algorithms to accelerate drug research and development (R&D). The company's BioHive-2 supercomputer, powered by Nvidia ...

Artificial intelligence (AI)-based drug developer Recursion said it has completed the fastest supercomputer to be wholly owned and operated by any pharmaceutical company worldwide, using technology ...

SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a Fast Company “Most Innovative Company” and leader in the artificial intelligence for drug discovery movement, today announced it will open-source a ...

BioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the most powerful supercomputers in the world across all industries as of May 2024. SALT LAKE CITY, May ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitors Salt Lake ...